Flunitrazolam or alternatively Flunazolam is a triazolobenzodiazepine (TBZD), which are benzodiazepine (BZD) derivatives, that has been sold online as a designer drug, and is a potent hypnotic and sedative drug similar to related compounds such as flunitrazepam, clonazolam and flubromazolam. It was first definitively identified and reported to the EMCDDA Early Warning System, by an analytical laboratory in Germany in October 2016,[1] and had not been described in the scientific or patent literature before this.[2] It is the triazole analogue of Flunitrazepam (Rohypnol). The addition of the triazole ring to the scaffold increases potency tremendously, this is evident as flunitrazolam is reported anecdotally to be active in the microgram level.

Flunitrazolam Structural Formula V.1.svg
Legal status
Legal status
  • 1-methyl-8-nitro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
CAS Number
PubChem CID
Chemical and physical data
Molar mass337.307 g·mol−1
3D model (JSmol)
  • O=[N](=O)c4ccc2-n1c(C)nnc1CN=C(c2c4)c3ccccc3F
  • InChI=1S/C17H12FN5O2/c1-10-20-21-16-9-19-17(12-4-2-3-5-14(12)18)13-8-11(23(24)25)6-7-15(13)22(10)16/h2-8H,9H2,1H3

See alsoEdit


  1. ^ Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA
  2. ^ Cornett EM, Novitch MB, Brunk AJ, Davidson KS, Menard BL, Urman RD, Kaye AD (June 2018). "New benzodiazepines for sedation". Best Practice & Research. Clinical Anaesthesiology. 32 (2): 149–164. doi:10.1016/j.bpa.2018.06.007. PMID 30322456.